Active ingredients

5 ml of the syrup contain 250 mg of inosine pranobex.

Indications

Inopranol is indicated for the treatment of reduced or dysfunctional cellular immunity and for the treatment of clinical symptoms of the following diseases:

• primary and secondary viral respiratory infections;
• viral infections caused by herpes simplex virus types 1 and 2, chickenpox virus, cytomegalovirus, Epstein-Barr virus;
• genital warts (Condyloma acuminata) - external lesions (with the exception of meatal (inside the anal canal) and perianal localization) - as monotherapy or as an adjunct to conventional local or surgical treatment;
• infections of the skin or mucous membranes, vulvovaginal (subclinical) infections or infections caused by HPV (human papilloma virus) associated with the endocervix - as part of complex therapy;
• viral hepatitis - as part of complex therapy;
• measles with a hard course or with complications;
• subacute sclerosing panencephalitis - as part of complex therapy.

Dosage and pharmaceutical form

120 ml of the syrup in a bottle, 1 bottle with a dosing device in a carton.